A.O. POZDNYAK¹, O.S. ELSUKOVA², E.A. NIKITINA²

 ¹KSMA — Branch Campus of the FSBEI FPE RMACPE MOH Russia, Kazan

²Kirov State Medical University, Kirov

 Contact details:

Nikitina E.A. — PhD (Medicine), Associate Professor of the Department of Internal Medicine

Address: 112 K. Marx St., 610027 Kirov, Russian Federation, tel.: +7-953-687-18-44, e-mail: nikitinae1991@mai.ru

The purpose was to investigate the dynamics of glycemic control parameters in patients with type 2 diabetes mellitus (T2DM) under the fixed combination (FC) of insulin glargine and lixisenatide over 24 months of observation.

Material and methods. The study included 35 patients with T2DM who had not achieved target glycemic control parameters during previous hypoglycemic therapy. Anthropometric data, glycated hemoglobin (HbA_1c), fasting glycemia, postprandial glycemia were assessed upon admission and 24 months after using the FC of insulin glargine and lixisenatide. Additionally, the frequency of symptomatic hypoglycemia and severe hypoglycemia during the observation period was analyzed.

Results. After 24 months of treatment with FC of insulin glargine and lixisenatide, a significant improvement in the analyzed parameters of glycemic control was achieved: a decrease in the level of HbA_1c, fasting glycemia and postprandial glycemia. The weight of patients decreased by an average of 6.8 kg (p = 0.040). Hypoglycemic conditions and severe hypoglycemia were not registered.

Conclusions. The appointment of FC of insulin glargine and lixisenatide to patients with type 2 diabetes mellitus led to an improvement in glycemic control and weight loss without increasing the risk of hypoglycemia.

Key words: type 2 diabetes mellitus, combined hypoglycemic therapy, glargine, lixisenatide, glycemic control.

REFERENCES

1. Shamkhalova M.Sh., Sukhareva O.Yu. Early intensification of type 2 diabetes mellitus therapy and achievement of target glycated hemoglobin HbA1c levels are necessary factors for reducing the risk of micro- and macrovascular complications. Sakharnyy diabet, 2023, vol. 26, no. 4, pp. 343–351 (in Russ.). DOI: 10.14341/DM13079
2. Dedov I.I., Shestakova M.V., Mayorov A.Yu. et al. Algorithms of specialized medical care for patients with diabetes mellitus. Sakharnyy diabet, 2023, vol. 26, no. 2S, pp. 1–157 (in Russ.). DOI: 10.14341/DM13042
3. Eliashevich S.O., Misharova A.P., Drapkina O.M. Remission of type 2 diabetes mellitus: possibilities of different dietary styles. Sakharnyy diabet, 2024, vol. 27, no. 2, pp. 168–173 (in Russ.). DOI: 10.14341/DM13050
4. Forst T., Choudhary P., Schneider D. et al. A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes. Diabetes Metab Res Rev, 2021, vol. 37 (6), p. e3418. DOI:https: 10.1002/dmrr.3418
5. Zhukova L.A., Andreeva N.S., Smirnova A.E. Use of a fixed combination of insulin glargine 100 U/ml and lixisenatide in patients with type 2 diabetes mellitus in real clinical practice. Effektivnaya farmakoterapiya, 2021, vol. 17, no. 31, pp. 14–16 (in Russ.). DOI: 10.33978/2307-3586-2021-17-31-14-16
6. American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of care in diabetes – 2023. Diabetes Care, 2023, vol. 46 (S1), pp. S140–S157. DOI: 10.2337/dc23-S009
7. Lixisenatide and iGlarLixi (insulin glargine/lixisenatide fixed-ratio combination) for the treatment of type2 diabetes mellitus [Internet], Food and Drug Administration, 2016 [cited 2020 Oct 29], available at: https://www.fda.gov/media/97767/download
8. Rosenstock J., Emral R., Sauque-Reyna L. et al. Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial. Diabetes Care, 2021, vol. 44 (10), pp. 2361–2370. DOI: 10.2337/dc21-0393
9. Kurkin D.V., Bakulin D.A., Morkovin E.I. et al. Fixed-ratio combinations of GLP-1 receptor agonists and basal insulin: a literature review. Problemy endokrinologii, 2024, vol. 70, no. 1, pp. 91–99 (in Russ.). DOI: 10.14341/probl13312
10. Kis J.T., Nagy G., Kovacs G. Effectiveness of IGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide, in people with type 2 diabetes. Diabetes Ther, 2021, vol. 12 (9), pp. 2517–2529. DOI: 10.1007/s13300-021-01128-5
11. Antsiferov M.B., Demidov N.A., Balberova M.A. et al. Efficiency of using a fixed combination of insulin glargine 100 U/ml and lixisenatide in patients with type 2 diabetes mellitus in real outpatient practice: a retrospective cohort study SOLO. Sakharnyy diabet, 2022, vol. 25, no. 2, pp. 112–119 (in Russ.). DOI: 10.14341/DM12809
12. Bala C., Cerghizan A., Mihai B.M. et al. Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro). BMJ Open, 2022, vol. 12 (5), p. e060852. DOI: 10.1136/bmjopen-2022-060852